Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported Gross Margin of 84.09% for Q1 2026, down 521.0% on a YoY basis from 19.97% in Q1 2025, and down 52.38% quarter-over-quarter from 176.58% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Gross Margin for 7 years, with the latest figure at 84.09% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 521.0% year-over-year to 84.09%; the trailing twelve-month figure through Mar 2026 stood at 106.31% (down 29.0% YoY), and the FY2025 full-year result was 100.0%, changed 0.0% from the prior year.
- Gross Margin for Q1 2026 stood at 84.09%, down from 176.58% in the prior quarter.
- The five-year high for Gross Margin was 236.37% in Q4 2023, with the low at 113.83% in Q2 2023.
- Historically, Gross Margin has averaged 67.96% across 5 years, with a median of 88.78% in 2024.
- The largest YoY upside for Gross Margin was 23581 bps in 2023 against a maximum downside of 9122 bps in 2023.
- Ginkgo Bioworks Holdings' Gross Margin stood at 0.56% in 2022, then soared by 42139 bps to 236.37% in 2023, then declined by 28 bps to 170.69% in 2024, then gained by 3 bps to 176.58% in 2025, then slumped by 52 bps to 84.09% in 2026.
- The last three Gross Margin figures came in at 84.09% (Q1 2026), 176.58% (Q4 2025), and 78.95% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | 84.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.09% |
| Dec 31, 2025 | 176.58% |
| Sep 30, 2025 | 78.95% |
| Jun 30, 2025 | 89.15% |
| Mar 31, 2025 | 89.30% |
| Dec 31, 2024 | 170.69% |
| Sep 30, 2024 | 88.78% |
| Jun 30, 2024 | 96.59% |
| Mar 31, 2024 | 100.00% |
| Dec 31, 2023 | 236.37% |
| Sep 30, 2023 | 100.00% |
| Jun 30, 2023 | -113.83% |
| Mar 31, 2023 | 12.03% |
| Dec 31, 2022 | 0.56% |
| Sep 30, 2022 | 0.55% |
| Jun 30, 2022 | -22.61% |
| Mar 31, 2022 | -31.84% |
| Dec 31, 2021 | -9.15% |
| Sep 30, 2021 | -32.45% |
| Jun 30, 2021 | -10.37% |